Developer docs
API playgroundTry for free, no card

Search company profiles

Locust Walk Partners

Full company profile

uuid00091d8

Namestring
Locust Walk Partners
Legal namestring
Locust Walk
Websiteurl
locustwalk.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Locust Walk is a global life science investment bank founded in Boston in 2008 that advises founders, executives, and board members of biotech and biopharmaceutical companies on strategic transactions. Its core service lines are sell-side strategic dealmaking (M&A advisory), licensing transactions, financing advisory, specialty pharma advisory, Asia cross-border transactions, and NewCo creation. The firm operates from five offices across three countries—Boston, San Francisco, Tokyo, Shanghai, and Beijing—and a 44-person team has closed more than 80 transactions over its 17-year history, including the $416M sale of Checkpoint Therapeutics to Sun Pharma and the ~$413M sale of DURECT to Bausch Health.

Revenue is generated through professional services advisory fees tied to transaction completion; pricing is not publicly disclosed and engagements are bespoke rather than subscription-based. The firm monetizes primarily via M&A success fees and licensing transaction commissions. Its primary customer segments are enterprise biotech and biopharma companies, with founders, executives, and board members acting as the buyer personas. Distribution is direct enterprise field sales through senior banker relationships, supplemented by thought-leadership content (Biotalk podcast, quarterly market reports, white papers) and co-hosted events such as the Align Summit with MassBio and McKinsey.

In May 2026 Locust Walk spun out Banyan BioInnovations, a development-driven investment firm that builds clinical-stage NewCos around best- or first-in-class drug assets, backed by more than $100M in initial commitments from life science investors and a strategic partnership with CRO Icon plc. This extends the platform beyond pure advisory into equity-linked company creation. The firm also previously took Locust Walk Acquisition Corp. public on NASDAQ (LWAC) in 2021, which merged with eFFECTOR Therapeutics. Locust Walk Securities, a wholly owned subsidiary, is a FINRA/SIPC member for securities offerings.

Short descriptiontext

Locust Walk is a global life science investment bank advising biotech and pharmaceutical founders, executives, and boards on M&A, licensing, financing, and NewCo creation, with offices in Boston, San Francisco, Tokyo, Shanghai, and Beijing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life science investment banking, biotech M&A advisory, strategic transaction advisory, NewCo creation services, biopharma licensing advisory
NAICS code1 code
  • Management Consulting Services54161
Product category
Life Science Investment Banking
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Transaction Advisory
TypeProfessional Services
Description

Locust Walk generates revenue through advisory fees for strategic transactions including M&A deals, licensing agreements, and financing processes. The firm acts as exclusive financial advisor to clients in sell-side and buy-side transactions, with compensation typically tied to transaction completion.

locustwalk.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Co-founder Mentality™
Description

A proprietary approach focused on partnering with innovators, characterized by local teams embedded in key markets and deep understanding of how science and data translate into actionable transactions.

locustwalk.com
+4 more records
Core offering1 text field

Locust Walk Partners is a global life science investment bank that provides strategic transaction advisory services to biotech, biopharma, and specialty pharma clients. Its services span sell-side M&A, buy-side advisory, licensing transactions, Asia cross-border deals, NewCo creation, and dedicated specialty pharma advisory. The firm also operates Banyan BioInnovations, a biopharma investment vehicle backed by more than $100M in initial commitments from life science investors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Premium of 217% upfront to 2,109% with CVRs for DURECT transaction
+1 more record
Product overview1 text field

Locust Walk is a global life science investment bank offering advisory and transaction services. The core offerings include sell-side strategic dealmaking, Asia cross-border transactions, NewCo creation, and specialty pharma advisory. The platform is powered by Banyan BioInnovations, an investment firm that builds clinical-stage companies around promising drug assets and provides centralized development infrastructure. Additional offerings include the Biotalk podcast, annual Align Summit conferences, and proprietary market reports and white papers on biopharma trends.

Product and service5 records
1Sell-Side Strategic Dealmaking
CategoryInvestment Banking Advisory
Description

Advisory mandate in which Locust Walk Partners acts as exclusive sell-side advisor to biotech, biopharma, and specialty pharma companies on strategic transactions.

2NewCo Creation
CategoryInvestment Banking Advisory
Description

Advisory service for biotech and biopharma clients seeking to spin out and capitalize NewCo entities built around clinical-stage or early commercial-stage drug assets.

3Asia Transactions
CategoryCross-Border Investment Banking
Description

Cross-border advisory service supporting U.S.–Asia life science transactions, executed via Locust Walk's offices in Tokyo, Shanghai, and Beijing.

4Specialty Pharma Advisory
CategoryInvestment Banking Advisory
Description

Dedicated advisory service for specialty pharma clients, addressing their specific strategic transaction and capital needs within Locust Walk's life science investment banking practice.

5Banyan BioInnovations
CategoryBiopharma Investment Platform
Description

Biopharma investment vehicle launched by Locust Walk Partners, seeded with more than $100M in initial commitments from life science investors and led by President Barbara White, supporting NewCo formation and capital deployment in life sciences.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Strategic collaboration and investment from Icon plc, a world-leading clinical research organization. This reflects a shared belief that a close partnership between sponsor and CRO leads to more thorough due diligence, better designed and faster executed trials, clear commercialization strategy, and a more collaborative approach to drug development. Icon provides clinical trial expertise to Banyan BioInnovations NewCos.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2006-01-01
Description

Members-only network connecting executive life science and investor communities. Founded in Philadelphia in 2006 by Geoff Meyerson, Locust Walk has played a key role in strengthening BioBreak's reach and impact.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Co-hosts the annual Align Summit with MassBio and McKinsey & Co., bringing together leaders from biopharma, academia, and the investment community to highlight emerging science and industry trends.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Co-hosts the annual Align Summit with MassBio and McKinsey & Co. to spotlight emerging biotech innovation and foster meaningful connections across the ecosystem.

5BIO International
Strategic tierMinorTypeGTM or Marketing Partner
Description

Provides executive development programming through BIO International, offering practical guidance on capital raising and company building.

locustwalk.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Provides executive development programming through LabCentral, offering practical guidance on capital raising and company building.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare investment banking team within Canaccord Genuity covering biotech M&A, licensing, and equity capital markets. Directly comparable boutique-to-mid-market life sciences advisory competitor.

TypeDirect peer
Description

Boutique investment bank focused on emerging growth and life sciences, providing capital markets and advisory services to small/mid-cap biotech. Highly comparable client segment and boutique positioning to Locust Walk.

TypeDirect peer
Description

Boutique investment bank with a healthcare and life sciences franchise advising biotech clients on capital markets and strategic transactions. Comparable niche boutique positioning in the life sciences advisory market.

TypeDirect peer
Description

Boutique investment bank specializing in life sciences and healthcare with a heavy focus on biotech equity raises and M&A. Closely matches Locust Walk's boutique scale and biotech vertical.

TypeDirect peer
Description

Boutique full-service investment bank with a long-standing healthcare and life sciences practice serving small- and mid-cap biotech clients. Comparable boutique scale and biotech mandate profile.

TypeBroad incumbent
Description

Larger full-service bank with a dedicated healthcare practice advising biotech, pharma, and life sciences tools clients. Overlaps with Locust Walk on M&A and licensing mandates from a broader platform.

TypeDirect peer
Description

Historically the most direct US life sciences-focused investment bank, providing M&A, equity research, and capital markets advisory to biotech and medtech clients. Highly comparable to Locust Walk in vertical focus and boutique-mid-market positioning.

TypeDirect peer
Description

Diversified mid-market bank with a sizeable healthcare M&A practice covering biopharma, medtech, and services. Directly comparable transaction profile and target client base to Locust Walk's biotech mandates.

TypeDirect peer
Description

Mid-market investment bank with a healthcare vertical covering biopharma M&A and capital raising. Comparable in client segment focus and deal size range to Locust Walk's mandate profile.

TypeBroad incumbent
Description

Bulge-bracket bank with one of the largest dedicated healthcare investment banking franchises. Competes with Locust Walk for biotech M&A and licensing mandates but offers far broader sector coverage and capital markets capabilities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Locust Walk Partners

Life Science Investment Bankinglocustwalk.com

Locust Walk is a global life science investment bank advising biotech and pharmaceutical founders, executives, and boards on M&A, licensing, financing, and NewCo creation, with offices in Boston, San Francisco, Tokyo, Shanghai, and Beijing.

What Locust Walk Partners does

Locust Walk is a global life science investment bank founded in Boston in 2008 that advises founders, executives, and board members of biotech and biopharmaceutical companies on strategic transactions. Its core service lines are sell-side strategic dealmaking (M&A advisory), licensing transactions, financing advisory, specialty pharma advisory, Asia cross-border transactions, and NewCo creation. The firm operates from five offices across three countries—Boston, San Francisco, Tokyo, Shanghai, and Beijing—and a 44-person team has closed more than 80 transactions over its 17-year history, including the $416M sale of Checkpoint Therapeutics to Sun Pharma and the ~$413M sale of DURECT to Bausch Health.

Revenue is generated through professional services advisory fees tied to transaction completion; pricing is not publicly disclosed and engagements are bespoke rather than subscription-based. The firm monetizes primarily via M&A success fees and licensing transaction commissions. Its primary customer segments are enterprise biotech and biopharma companies, with founders, executives, and board members acting as the buyer personas. Distribution is direct enterprise field sales through senior banker relationships, supplemented by thought-leadership content (Biotalk podcast, quarterly market reports, white papers) and co-hosted events such as the Align Summit with MassBio and McKinsey.

In May 2026 Locust Walk spun out Banyan BioInnovations, a development-driven investment firm that builds clinical-stage NewCos around best- or first-in-class drug assets, backed by more than $100M in initial commitments from life science investors and a strategic partnership with CRO Icon plc. This extends the platform beyond pure advisory into equity-linked company creation. The firm also previously took Locust Walk Acquisition Corp. public on NASDAQ (LWAC) in 2021, which merged with eFFECTOR Therapeutics. Locust Walk Securities, a wholly owned subsidiary, is a FINRA/SIPC member for securities offerings.

Locust Walk Partners firmographics

Firmographics
Name
Locust Walk Partners
Legal name
Locust Walk
Website
https://locustwalk.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Locust Walk is a global life science investment bank advising biotech and pharmaceutical founders, executives, and boards on M&A, licensing, financing, and NewCo creation, with offices in Boston, San Francisco, Tokyo, Shanghai, and Beijing.
Ownership category
akta.pro rank

Where Locust Walk Partners is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Locust Walk Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Strategic Transaction Advisory: Locust Walk generates revenue through advisory fees for strategic transactions including M&A deals, licensing agreements, and financing processes. The firm acts as exclusive financial advisor to clients in sell-side and buy-side transactions, with compensation typically tied to transaction completion.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Locust Walk Partners product offering

Product offering

Core offering

Locust Walk Partners is a global life science investment bank that provides strategic transaction advisory services to biotech, biopharma, and specialty pharma clients. Its services span sell-side M&A, buy-side advisory, licensing transactions, Asia cross-border deals, NewCo creation, and dedicated specialty pharma advisory. The firm also operates Banyan BioInnovations, a biopharma investment vehicle backed by more than $100M in initial commitments from life science investors.

Product overview

Locust Walk is a global life science investment bank offering advisory and transaction services. The core offerings include sell-side strategic dealmaking, Asia cross-border transactions, NewCo creation, and specialty pharma advisory. The platform is powered by Banyan BioInnovations, an investment firm that builds clinical-stage companies around promising drug assets and provides centralized development infrastructure. Additional offerings include the Biotalk podcast, annual Align Summit conferences, and proprietary market reports and white papers on biopharma trends.

Differentiator

Problem solved

Functional benefit

Brands

  • Co-founder Mentality™: A proprietary approach focused on partnering with innovators, characterized by local teams embedded in key markets and deep understanding of how science and data translate into actionable transactions.
  • Banyan BioInnovations
  • Locust Walk Acquisition Corp.
  • Biotalk
  • Align Summit

Products and services

  • Sell-Side Strategic Dealmaking Advisory mandate in which Locust Walk Partners acts as exclusive sell-side advisor to biotech, biopharma, and specialty pharma companies on strategic transactions.
  • NewCo Creation Advisory service for biotech and biopharma clients seeking to spin out and capitalize NewCo entities built around clinical-stage or early commercial-stage drug assets.
  • Asia Transactions Cross-border advisory service supporting U.S.–Asia life science transactions, executed via Locust Walk's offices in Tokyo, Shanghai, and Beijing.
  • Specialty Pharma Advisory Dedicated advisory service for specialty pharma clients, addressing their specific strategic transaction and capital needs within Locust Walk's life science investment banking practice.
  • Banyan BioInnovations Biopharma investment vehicle launched by Locust Walk Partners, seeded with more than $100M in initial commitments from life science investors and led by President Barbara White, supporting NewCo formation and capital deployment in life sciences.

Quantifiable outcome

  • Premium of 217% upfront to 2,109% with CVRs for DURECT transaction
  • +1 more outcomes

Companies that use Locust Walk Partners

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Locust Walk Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Locust Walk Partners partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Icon plccoreStrategic or Co-development Partner · 5 May 2026Strategic collaboration and investment from Icon plc, a world-leading clinical research organization. This reflects a shared belief that a close partnership between sponsor and CRO leads to more thorough due diligence, better designed and faster executed trials, clear commercialization strategy, and a more collaborative approach to drug development. Icon provides clinical trial expertise to Banyan BioInnovations NewCos.
  • BioBreakminorGTM or Marketing Partner · 1 January 2006Members-only network connecting executive life science and investor communities. Founded in Philadelphia in 2006 by Geoff Meyerson, Locust Walk has played a key role in strengthening BioBreak's reach and impact.
  • MassBiocoreGTM or Marketing PartnerCo-hosts the annual Align Summit with MassBio and McKinsey & Co., bringing together leaders from biopharma, academia, and the investment community to highlight emerging science and industry trends.
  • McKinsey & CompanycoreGTM or Marketing PartnerCo-hosts the annual Align Summit with MassBio and McKinsey & Co. to spotlight emerging biotech innovation and foster meaningful connections across the ecosystem.
  • BIO InternationalminorGTM or Marketing PartnerProvides executive development programming through BIO International, offering practical guidance on capital raising and company building.
  • LabCentralminorGTM or Marketing PartnerProvides executive development programming through LabCentral, offering practical guidance on capital raising and company building.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Locust Walk Partners competitors and assessment

Company assessment

Direct peers

  • Canaccord Genuity (Healthcare): Healthcare investment banking team within Canaccord Genuity covering biotech M&A, licensing, and equity capital markets. Directly comparable boutique-to-mid-market life sciences advisory competitor.
  • ThinkEquity: Boutique investment bank focused on emerging growth and life sciences, providing capital markets and advisory services to small/mid-cap biotech. Highly comparable client segment and boutique positioning to Locust Walk.
  • Chardan Capital Markets: Boutique investment bank with a healthcare and life sciences franchise advising biotech clients on capital markets and strategic transactions. Comparable niche boutique positioning in the life sciences advisory market.
  • H.C. Wainwright & Co. Boutique investment bank specializing in life sciences and healthcare with a heavy focus on biotech equity raises and M&A. Closely matches Locust Walk's boutique scale and biotech vertical.
  • Maxim Group: Boutique full-service investment bank with a long-standing healthcare and life sciences practice serving small- and mid-cap biotech clients. Comparable boutique scale and biotech mandate profile.
  • Leerink Partners: Historically the most direct US life sciences-focused investment bank, providing M&A, equity research, and capital markets advisory to biotech and medtech clients. Highly comparable to Locust Walk in vertical focus and boutique-mid-market positioning.
  • Piper Sandler (Healthcare Investment Banking): Diversified mid-market bank with a sizeable healthcare M&A practice covering biopharma, medtech, and services. Directly comparable transaction profile and target client base to Locust Walk's biotech mandates.
  • Robert W. Baird (Healthcare Investment Banking): Mid-market investment bank with a healthcare vertical covering biopharma M&A and capital raising. Comparable in client segment focus and deal size range to Locust Walk's mandate profile.

Broad incumbents

  • Guggenheim Securities (Healthcare): Larger full-service bank with a dedicated healthcare practice advising biotech, pharma, and life sciences tools clients. Overlaps with Locust Walk on M&A and licensing mandates from a broader platform.
  • Jefferies (Healthcare Group): Bulge-bracket bank with one of the largest dedicated healthcare investment banking franchises. Competes with Locust Walk for biotech M&A and licensing mandates but offers far broader sector coverage and capital markets capabilities.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Locust Walk Partners social profiles

Digital presence

Locust Walk Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Locust Walk Partners leadership team

Management profile

Number of profiles

Profiles4 records

Locust Walk Partners subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Locust Walk Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Locust Walk Partners M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Locust Walk Partners

What does Locust Walk Partners do?

Locust Walk Partners is a global life science investment bank that provides strategic transaction advisory services to biotech, biopharma, and specialty pharma clients. Its services span sell-side M&A, buy-side advisory, licensing transactions, Asia cross-border deals, NewCo creation, and dedicated specialty pharma advisory. The firm also operates Banyan BioInnovations, a biopharma investment vehicle backed by more than $100M in initial commitments from life science investors.

Is Locust Walk Partners a public or private company?

Locust Walk Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Locust Walk Partners founded?

Locust Walk Partners was founded in 2008. It employs 11 to 50 people.

Where is Locust Walk Partners based?

Locust Walk Partners is headquartered in Boston, United States, in the North America region.

How does Locust Walk Partners make money?

One revenue line is on record: strategic Transaction Advisory.

Who are Locust Walk Partners's main competitors?

Direct peers on record are Canaccord Genuity (Healthcare), ThinkEquity, Chardan Capital Markets, H.C. Wainwright & Co., Maxim Group, Leerink Partners, Piper Sandler (Healthcare Investment Banking) and Robert W. Baird (Healthcare Investment Banking). Broad incumbents are Guggenheim Securities (Healthcare) and Jefferies (Healthcare Group).

Does Locust Walk Partners have an API?

No public API is recorded for Locust Walk Partners.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsStockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking CapitalBiotech IPOs surged 573% in 2026, with nine deals totaling $2.4 billion in Q3, while licensing deals fell to $48 billion. China led licensing at 58% of value, and Locust Walk's CEO said the cycle is not over.LocustwalkNavigating the MedTech Fundraising Environment – Locust WalkLocust Walk provides an analysis of the MedTech fundraising landscape, noting that while capital is constrained for companies in the 'chasm' between early-stage development and commercialization, late-stage financings exceeding $25 million remain active. The firm advises entrepreneurs to focus on product-market fit, clear use of proceeds, risk relevance, and team capabilities to secure investment from diverse sources such as venture firms and sovereign wealth funds.MintzDoing Life Sciences Deals in 2024Mintz hosted a panel on structuring life sciences transactions with GSK, J&J, Locust Walk, and Astria. Panelists said competitive tension and year-end timing speed deals, and licenses dominate biotech deals at 75%. They advised preparation and clear communication to accelerate negotiations.PR NewswireKernal Biologics to Present at Locust Walk RNA Innovation ConferenceKernal Biologics announced that Co-founder and CEO Yusuf Erkul will present the company's mRNA 2.0 immunotherapy platform at the Locust Walk RNA Innovation Conference on May 9, 2023. The platform uses a machine learning-backed computational pipeline to analyze transcriptome and translatome datasets for discovering cell-specific mRNA sequence features, enabling cell-specific therapeutic mRNAs with an onco-selective approach. The first therapeutic products of this platform, including KR-335, initially focus on immuno-oncology applications for cancer treatment.GlobeNewswireAnima Biotech to Present at Locust Walk RNA Innovation ConferenceAnima Biotech announced that Iris Alroy, Ph.D., will present its mRNA Lightning platform at the Locust Walk RNA Innovation Conference on May 9, 2023. The presentation will highlight key results from lead programs in Immunology and Oncology, including small molecule mRNA modulators for diseases like fibrosis and cancer.ZapierHealthcare SPAC Locust Walk Acquisition prices upsized $153 million IPO at $10Locust Walk Acquisition raised $153 million by offering 15.3 million units at $10, offering 2.3 million more than planned. Each unit includes one share and one-third of a warrant exercisable at $11.50. The company plans to list on Nasdaq under LWACU, with Cantor Fitzgerald as lead manager.GlobeNewswireInnovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug CandidateInnovation Pharmaceuticals engaged Locust Walk to lead out-licensing negotiations for rights to oral rinse Brilacidin for oral mucositis. The Phase 3-ready, FDA Fast Track asset previously had a Phase 2 trial meeting primary endpoints. The company plans to advance Brilacidin into Phase 3 development subject to available financial resources.GlobeNewswireInnovation Pharmaceuticals Engages Locust Walk, A Global Life Sciences Transaction FirmInnovation Pharmaceuticals engaged Locust Walk, a global life sciences transaction firm, to help maximize asset value. The company's Brilacidin was licensed to Alfasigma in July 2019 for ulcerative proctitis, and it plans to advance Brilacidin oral rinse into Phase 3. The engagement aims to unlock shareholder value through further transactions.PR NewswireLocust Walk Further Expands Financing Team with Appointments of Neil Higgins and Turner GrantLocust Walk, a global life science transaction firm, announced the appointments of Neil Higgins as Managing Director of Financing and Turner Grant as Senior Vice President of Financing, both reporting to Brian Coleman. Higgins previously spent nearly 20 years in equity sales at Bank of America, Piper Jaffray, and Jefferies, while Grant spent 22 years raising capital at Lehman Brothers, SunTrust Robinson Humphrey, and most recently Chardan Capital Markets. The firm noted it raised $80MM for private companies in 2018 and is expanding its financing team to help biopharma and medtech companies access capital from venture capital, crossover, hedge fund, family office, and other institutional sources.PR NewswireCellect Engages Locust Walk to Support Business Development Activities for Cellect's ApoGraft™Cellect Biotechnology Ltd. has engaged Locust Walk to facilitate strategic licensing deals and global pharmaceutical partnerships for its ApoGraft stem cell selection technology. This business development initiative aims to commercialize the platform by securing collaborations with pharma companies, medical device firms, and research centers. The move positions Cellect to expand its market presence in the stem cell therapeutics sector.